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Abstract. The aim of the present study was to evaluate 
the oncologic safety and reproductive outcome in patients 
with stage I epithelial ovarian cancer (EOC) treated with 
fertility-sparing surgery (FSS). Women aged ≤40 years with 
stage I EOC who had undergone FSS between 2000 and 2010 
were retrospectively reviewed. Survival was examined using 
the Kaplan-Meier method and statistical significance was 
analyzed using the log-rank test. A total of 29 EOC patients 
(stage IA, n=14; stage IC1 n=6; stage IC3, n=9) from seven 
participating institutions belonging to the Tohoku Gynecologic 
Cancer Unit were enrolled. After a median follow-up duration 
of 60.6 months (range, 6‑135 months), five patients (17.2%) 
experienced tumor recurrence. The respective five-year 
relapse-free survival (RFS) and overall survival (OS) rates 
were 90.9 and 100% for stage IA/IC1, and 43.8 and 87.5% 
for stage IC3. Significant differences in RFS were observed 
between stage IA/IC1 and IC3 patients (P=0.026). However, 
there was no significant difference in OS between patients 
with 1A/1C1 and those with 1C3 (P=0.712). After FSS, seven 
pregnancies occurred in five patients, which resulted in the 
birth of six healthy children. The results of the present study 
confirmed that FSS may be an acceptable treatment method 
for stage IA and IC1 EOC, exhibiting a favorable reproductive 
outcome. However, the safety of FSS for treating stage IC3 
EOC is uncertain and warrants further investigation.
Introduction
Epithelial ovarian cancer (EOC) can occur at any age but is 
most commonly diagnosed in postmenopausal females, as the 
peak incidence is between the ages of 50 and 60 years. Standard 
EOC management involves primary surgery, including total 
abdominal hysterectomy, bilateral salpingo-oophorectomy, 
pelvic/para-aortic lymph node (LN) dissection, omentectomy 
and tumor debulking, followed by taxane/platinum-based 
adjuvant chemotherapy. Recently, women tend to give birth 
to their first child at an older age, and the diagnosis of EOC 
before childbearing has become more frequent. Because 
approximately 14% of all EOC cases occur in women aged 
under 40 years, some patients may choose fertility preserva-
tion (1). Fertility-sparing surgery (FSS), with preservation of 
the contralateral ovary and uterus, for women of reproductive 
age has been indicated for patients with stage I EOC (2). It is 
estimated that 7‑8% of all stage I EOC patients are younger 
than 35 years of age (3).
According to the recent National Comprehensive Cancer 
Network (NCCN) guidelines, patients with unilateral stage 
(IA or IC) EOC based on comprehensive surgical staging can 
undergo FSS, regardless of grade (G) and histology (4). The 
present clinical guidelines of the European Society of Medical 
Oncology (ESMO) state that young women with stage IA or 
IC and favorable histological characteristics, such as non-clear 
cell carcinoma (CCC) and G1 or G2 tumors, are subject to 
FSS only following complete surgical staging that includes 
lymphadenectomy (5). However, regarding patients with high 
risk prognostic factors such as G3/CCC or stage IC subtypes, 
the safety of FSS is controversial. In the present study, we 
investigated the recurrence rates, survival, reproductive and 
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obstetrical outcomes for women with stage I EOC treated with 
FSS.
Patients and methods
Study design. After obtaining the institutional review board 
approval of each of the seven participating institutions 
belonging to the Tohoku Gynecologic Cancer Unit (TGCU), 
the medical records of 29 patients with stage I EOC who had 
undergone FSS between 2000 and 2010 were retrospectively 
analyzed.
Participants. Additional criteria included that all patients 
were aged ≤40 years at the time of initial diagnosis, strongly 
desired to retain their fertility, and were informed about the 
possible risks and benefits of FSS. Exclusion criteria were 
non-epithelial histological type tumors (germ cell tumors 
and sex-cord stromal tumors), borderline malignant tumor, 
unclassified adenocarcinoma, and advanced EOC (≥stage II). 
All patients underwent FSS, such as unilateral oophorectomy 
or ovarian cystectomy with conservation of the uterus and 
contralateral ovary. Pathological diagnosis for histologic cell 
type, tumor differentiation and disease staging were performed 
in each institution. Staging was determined according to 
the International Federation of Gynecology and Obstetrics 
(FIGO) classification (2014). Centralized pathological review 
by a pathologist was performed at Fukushima Medical 
University Hospital to confirm tumor histology type and 
histologic differentiation. Following completion of primary 
treatment, patients were examined every 1-3 months during 
the first 2 years, every 3‑6 months during the next 3 years and 
yearly thereafter. Recurrences were diagnosed during regular 
follow-up visits and confirmed on computed tomographic 
and/or magnetic resonance imaging scans. 
All patients had provided written informed consent for 
surgery. The present study was approved by the Research 
Ethics Committee of each of the seven participating institu-
tions belonging to the TGCU: Fukushima Medical University 
School of Medicine (Fukushima, Japan), Tohoku University 
Graduate School of Medicine (Sendai, Japan), Miyagi Cancer 
Center (Natori, Japan), Yamagata University School of 
Medicine (Yamagata, Japan), Iwate Medical University School 
of Medicine (Morioka, Japan), Akita University School of 
Medicine (Akita, Japan) and Hirosaki University School of 
Medicine (Hirosaki, Japan).
Statistical analysis. Overall survival (OS) and relapse-free 
survival (RFS) were evaluated as clinical outcomes. Survival 
distributions were calculated using the Kaplan-Meier method, 
and statistical significance was determined using the log‑rank 
test. Values of P<0.05 were considered statistically significant. 
Statistical analysis of data was performed using SPSS 25 (IBM 
Corp., Armonk, NY, USA).
Results
Clinicopathological characteristics. A total of 29 patients 
with stage I EOC who were treated with FSS were enrolled 
in the present study. The clinicopathological characteris-
tics of all patients are shown in Table I. The mean age was 
27.2 years (range, 12 to 39 years), and the numbers of patients 
with stage IA and stage IC EOC were 14 and 15, respectively. 
The most frequent histological type was mucinous (16 cases, 
55.2%), followed by serous (five, 17.2%) and endometrioid (five, 
17.2%). Tumor differentiation was 13 (44.8%), 10 (34.5%) and 6 
(20.7%) for G1, G2 and G3/CCC, respectively. Adjuvant chemo-
therapy was given to 19 (65.5%) patients with stage IA (7/14, 
50%) and stage IC (12/15, 80%) EOC (data not shown). Eighteen 
patients underwent platinum-based chemotherapy, and one 
patient underwent oral etoposide. After a median follow-up 
of 60.6 months (range, 6-135 months), the clinical outcomes 
were as follows: 26 patients (89.7%) had no evidence of disease 
(NED); one (3.4%) patient was alive with disease (AWD); 
and two patients (6.9%) were dead of disease (DOD). 
Twenty-one patients did not experience a change in menstrua-
tion status after treatment, and two patients had amenorrhea. 
After FSS, five patients achieved seven pregnancies, resulting 
in the birth of six healthy children. Among the five patients, 
four had received platinum-based chemotherapy, and their 
babies showed no congenital malformations. As for primary 
symptoms, abdominal symptoms accounted for over 80% of 
all symptoms followed by atypical genital bleeding (10.3%).
Clinical outcome of FSS in patients with stage I EOC. 
Recurrence was identified during the follow-up period in 
five patients (17.2%) whose clinical details are described in 
Table II. The recurrence sites were: the pelvis n=2; pelvic LN 
n=1; cervical LN n=1; and pelvic LN and peritoneum n=1. 
Median duration from primary treatment to recurrence was 
43.8 months (range, 17‑55 months). After all five patients with 
recurrences were treated as outlined in Table II, two patients 
had NED, one patient was AWD, and two patients were DOD 
at 23 and 71 months after diagnosis. The estimated survival 
rate of all patients was 95.7% at five years and 89.3% at ten 
years.
We compared the OS and RFS for histological 
differentiation and FIGO stage. All patients were classified into 
two subgroups from the point of view of prognostic factors. 
The first subgroup was G1/G2 vs. G3/CCC for histological 
differentiation and the second subgroup was IA/IC1 vs. 1C3 
for stage. As for the patients with G1/G2 and G3/CCC, the 
five‑year RFS rates were 78.4 and 60%, respectively, and 
the five‑year OS rates were 94.1 and 100%, respectively. No 
significant differences in RFS and OS were seen between the 
patients (RFS P=0.646, OS P=0.356; Fig. 1). With regard to 
the patients with stage IA/IC1 and 1C3 EOC, the five‑year RFS 
rates were 90.9 and 43.8%, respectively, and the five‑year OS 
rates were 100 and 87.5%, respectively. Significant differences 
in RFS were seen between the patients (P=0.026; Fig. 2A), 
although there was no significant difference in OS (P=0.712; 
Fig. 2B).
Discussion
The final goal of FSS is curable, safe and good reproductive and 
obstetrical outcomes in cases of early EOC in young women 
who desire childbearing. In our series, after a median follow-up 
of 60.6 months, the recurrence rate among the 29 stage I EOC 
patients who underwent FSS was 13% (5 of 29), which is 
similar to the majority of trials focusing on early-stage EOC, 
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treated with either a radical approach or FSS, falling between 
the reported 4 and 15% (6). Schlaerth et al (7), reported that 
the five‑year survival data for 123 patients who underwent 
surgical treatment for stage I EOC for fertility-preservation 
revealed no significant differences in five‑year RFS (84% 
vs. 78%) or OS (84% vs. 82%) when compared to standard 
surgery. In addition, a recent study reported that FSS was not 
associated with increased risk of death in young women with 
stage I EOC compared with conventional surgery (8). The 
present study revealed a five‑year RFS rate of 73.1% (data not 
shown) and an OS rate of 95.7%, which are consistent with the 
results of previous reports (7,9).
There have been many studies that confirm the safety of 
FSS for stage I EOC patients. Histologic tumor grade is one 
of the most important risk factors of recurrence of EOC. In a 
recent comprehensive literature review of 1,150 patients who 
underwent FSS, 21 teams reported that there were 139 relapsed 
patients. The recurrence rate in patients with stage IA/IC of 
G1/G2 tumors (7‑11%) was lower than that of patients with 
G3 tumors (23‑29%) (6). G3 tumor is an independent risk 
factor and is associated with distant relapse and lower OS (6). 
In addition, it has been reported that although FSS can be 
safe and appropriate for patients with G1/G2 tumors, it is not 
recommended for patients with G3 tumors (10).
CCC has a great risk of recurrence and poor prognosis in 
comparison with other pathological types (serous, endome-
trioid, and mucinous) of EOC because of a relative resistance to 
first line platinum‑based chemotherapy (11). According to the 
American College of Obstetricians and Gynecologists (ACOG) 
and ESMO guidelines, CCC is classified as an unfavorable 
histological type for FSS (5,12). In a recent study, G3 and 
CCC were the only independent risk factors for the survival of 
stage I EOC patients of reproductive age (13). It has been noted 
that the time to give pregnancy permission after FSS should be 
considered carefully, because the majority of reported recur-
rences of CCC occurred at extraovarian locations within the 
first two years following initial surgical staging (14). On the 
other hand, the selection criteria for FSS could include patients 
with stage IA CCC (15,16). There was no significant difference 
in the RFS and OS between the EOC patients with G1/G2 and 
those with G3/CCC in the current study (Fig. 1), and histo-
logical grading did not show prognostic factors. The reason for 
this could be that the number of subjects in our study was too 
small to evaluate the appropriateness of FSS for patients with 
Table I. Continued.
Primary symptom, cn (%) 
  Abdominal symptom 24 (82.8)
  Atypical genital bleeding 3 (10.3)
  Medical examination 2 (6.9)
  Unknown 1 (3.4)
aClear cell is not graded. bPregnancy in 5 patients, Birth in 4 
patients. cOne patient exhibited two symptoms. USO, unilateral 
salpingo-oophrectomy; OMT, omentectomy; LA, lymphadenectomy; 
NED, no evidence of disease; AWD, alive with disease; DOD, dead 
of disease.
Table I. Clinicopathlogical characterstics of patients treated 
with FSS.
Mean age, years (range) 27.2 (12‑39)
Surgical procedures, n (%) 
  Cystectomy 1 (3.5)
  USO 10 (34.5)
  USO, OMT 3 (10.3)
  USO, OMT, LA 15 (51.7)
Tumor histology, n (%) 
  Mucinous 16 (55.2)
  Serous 5 (17.2)
  Endometrioid 5 (17.2)
  Clear cell 3 (10.4)
Grade, an 
  G1 13
  G2 10
  G3 3
FIGO stage, n (%) 
  IA 14 (48.3)
  G1 6
  G2 5
  G3 2
Clear cell 1
  IC1 6 (20.7)
  G1 3
  G2 3
  G3 0
Clear cell 0
  IC3 9 (31.0)
  G1 4
  G2 2
  G3 1
  Clear cell 2
Adjuvant chemotherapy, n (%) 
  Yes 19 (65.5)
  No 10 (34.5)
Recurrence, n (%) 
  No 24 (82.3)
  Yes 5 (17.2)
Clinical outcome, n (%) 
  NED 26 (89.7)
  AWD 1 (3.4)
  DOD 2 (6.9)
Menstruation, n 
  Regular   21
  Irregular 1
  Amenorrhea 2
  Unknown 5
Reproductive outcome, bn 
  Parity 7
  Birth  6
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poor differentiation and unfavorable histology. Therefore, FSS 
should be considered with caution in G3/CCC patients.
Staging is also an important factor for prognosis of EOC 
patients who undergo FSS. A previous study suggested that 
patients with stage IA EOC have survival approaching 
94%, whereas it is approximately 84% for patients with IC 
EOC (17). FIGO staging represents a change of stage IC if cyst 
rupture is noted preoperatively or postoperatively. Although in 
patients with intraoperative rupture, survival was not different 
from patients whose tumors had intact capsules (85 and 78%, 
respectively), it was significantly different from patients with 
preoperative rupture (59%) (18). Recently, the 2014 FIGO 
staging system modified stage IC and subdivided it into three 
new clinically and prognostically more relevant subgroups (19). 
Although no significant survival differences in patients have 
been observed between stage IC1 and stage IA, the survival of 
stage IC2/3 has been reported to be worse than that of stage IA 
and IC1 (20,21). In a systematic review, the recurrence rate of 
Figure 1. Kaplan-Meier survival curves of 29 patients with stage I EOC. (A) Relapse-free survival and (B) overall survival curves for grade 1/2 and grade 3/CCC. 
CCC, non-clear cell carcinoma.
Table II. Clinical details of relapsed patients.
     Adjuvant Site of  Salvage
Case Age Stage Histology Grade chemotherapy recurrence RFS (mo) recurrence Status OS (mo)
1 33 IC3 Serous 1 Yes Pelvis 40 Radical surgery NED 119
2 36 IC3 Clear cell  Yes Pelvic LN 55 Radical surgery NED 107
3 27 IC3 Serous 3 Yes Pelvis 54 Radical surgery AWD 104
4 19 IC3 Mucinous 2 No Cervical LN 17 CCRT DOD 23
5 21 IA Serous 1 Yes Pelvic LN Peritoneum 53 Chemotherapy DOD 71
LN, lymph node; CCRT, concurrent chemoradiotherapy; NED, no evidence of disease; AWD, alive with disease; DOD, dead of disease; 
RFS, relapse-free survival; OS, overall survival.
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stage IC2/3 (23%) after FSS was significantly higher than that 
of stage IC1 (12%) (14).
Although we were unable to investigate preoperative 
rupture in the current study because patients with IC2 were 
not included in the study population, cytology positive as 
stage IC3 indicated a high risk of recurrence in the patients who 
underwent FSS (Fig. 2A). Probably due to a small sample size, 
the recurrence rate in the IC3 and G3/CCC patients was very 
high (67%, 2 of 3; Table II). However, there was no significant 
difference in OS (Fig. 2B). Although the recurrence rate of 
stage IC3 (4/9) was more than that of stage IA/IC1 (1/20), the 
mortality rates were similar because three patients with recur-
rence in stage IC3 were curative. Further studies with larger 
sample sizes are needed to identify the differences in OS.
According to previous studies, recurrence in the remaining 
ovary is likely to be successfully treated with surgery and 
chemotherapy, and does not affect the long-term survival of 
FSS patients (14,22,23). However, patients who had relapse in 
LNs or PC, which is typical of clear cell histology, had a poor 
prognosis (24). Compared with G1/G2 tumors, G3 tumors give 
rise to a higher rate of extraovarian recurrences (6,14). In the 
current study, the recurrence sites were the pelvis (n=2), LN 
and peritoneum (n=1) and LN (n=2), and there were no patients 
showing recurrence exclusively in the residual ovary (Table II). 
The extraovarian recurrence rate of the G1/G2 tumors (3/23, 
13%) was lower than that of the G3/CCC tumors (2/6, 33.3%), 
and this result was similar to that of a previous report (G1; 9%, 
G2; 11.2%, G3; 23.5%, CCC; 15.3%) (25). The extraovarian 
recurrence rate in patients with positive cytology (4/9, 44.4%) 
also showed a higher proportion than that in patients with 
negative cytology (1/20, 5%) in the present study.
The reproductive outcome was considered favorable in our 
series. Most patients had regular menstruation after surgery and 
chemotherapy. Four patients, who underwent chemotherapy, 
gave birth to six infants without congenital anomalies. Recent 
studies have described good reproductive outcomes after 
chemotherapy for malignant tumors (10,13). The usefulness of 
a wedge biopsy of the normal-appearing contralateral ovary 
in FSS is unknown. In recent data, an incidence of micro-
scopic metastasis in the opposite normal looking ovaries was 
reported to be approximately 0‑5% (10,26). However, none of 
the patients who underwent FSS had microscopic metastases 
in their macroscopically normal ovaries detected by routine 
biopsies (27,28). In another series, micrometastasis in an ovary 
with a grossly normal appearance was very rare (3 of 118, 
2.5%) (29). The survival of patients with an isolated ovarian 
recurrence is better than that of patients with other types of 
recurrence (22). In the present study, among the five patients 
who had recurrence, none experienced said recurrence on the 
contralateral ovary. As wedge biopsy can cause mechanical 
Figure 2. Kaplan-Meier survival curves of 29 patients with stage I EOC. (A) Relapse-free survival and (B) overall survival curves for stage IA/IC1 and 
stage IC3.
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infertility or ovarian failure, if the opposite ovary is of normal 
size, shape, and position, surgical evaluation should not be 
routinely performed.
There were some limitations in the present study. The first 
and biggest limitation is the small sample size, compared to 
those of other multicenter research studies. Survival evaluation 
of detailed classifications, including histological tumor grade, 
histology and staging, could not be performed. A larger sample 
size would likely provide more definitive results. Secondly, our 
study was not a randomized controlled trial, but a retrospective 
study, and did not have sufficient power to provide a definitive 
conclusion. Thirdly, although obstetric outcome is as important 
as oncological safety for patients receiving FSS, we unfortu-
nately could not present data on reproductive outcome because 
some young patients who were married could not be followed 
up on for adequate periods and several unmarried patients were 
included in this study. Fourthly, we were unable to obtain the 
total number and information of all EOC patients in each institu-
tion. Therefore, we could not compare FSS and radical surgery 
for stage I EOC. Finally, lymphadenectomy was not performed 
for some patients because they had often undergone surgery for a 
presumed benign tumor or emergency. LN evaluation is recom-
mended in the surgical treatment of early stage EOC according 
to the FIGO criteria, in order to perform accurate clinical staging 
and to select an adequate adjuvant systemic chemotherapy.
In conclusion, our data confirmed that FSS could be consid-
ered in the treatment of fertile women with stage IA and IC1 
EOC and has a sufficient reproductive and obstetrical outcome. 
However, we were unable to confirm the safety of FSS for patients 
with stage IC3 EOC. Since the increased risk of stage I EOC 
in patients with positive cytology is mainly related to a higher 
incidence of extraovarian spread rather than to a higher relapse 
rate in the preserved ovary, these patients should be carefully 
informed about their prognosis when FSS is chosen. Our results 
are consistent with those of previous studies and we believe 
that these data can help treat early EOC in young women who 
wish to bear children following treatment. In future, prospective 
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